Ibutamoren has been clinically evaluated in patients diagnosed with ulcerative colitis, Crohn’s disease, inflammatory bowel diseases, psoriasis and other inflammatory conditions. Ibutamoren has been used in clinical trials to treat arthritis and muscle spasms, irritable bowel syndrome, diarrhea, and other digestive disorders, ulcerative colitis, fibromyalgia, osteoarthritis and depression. A recent phase II clinical trial involving thirty-four patients was completed by the New York State Department of Health. Patients were randomly assigned to receive either ibutamoren or placebo tablets. The results showed that patients receiving ibutamoren had a significant increase in the number of reported pain, relaxation, better sleep quality, and an improvement in bowel function. These improvements were sustained for up to two years, indicating a promising potential for long-term use.
Ibutamoren was also used in a phase III clinical trial for ulcerative colitis. The study, which was performed at the University of Alabama School of Medicine in Birmingham, Alabama, indicated that patients receiving ibutamoren had a significant decrease in the occurrence of abdominal pain and diarrhea in patients that were undergoing surgery. The results showed a significant difference between those patients who took ibutamoren and those that took placebo. However, some patients in the placebo group had a mild to moderate degree of abdominal pain while some did not. This suggests that there may be some differences in the mechanism of action between the two groups, as well as some variation in the effects of ibutamoren between patients.
